Drugging the foam cell: identifying P2Y6 antagonists that limit atherosclerosis

Katey J Rayner

DOI: https://doi.org/10.1093/eurheartj/ehad846

IF: 39.3

2024-01-22

European Heart Journal

Abstract:Leveraging data from human datasets, together with mechanistic studies in cells and animals, Li et al . identified a new drug candidate for the antagonism of P2Y 6 signalling in foam cells that could prevent the development of atherosclerosis. Screening of human and mouse atherosclerotic datasets suggested that P2Y 6 expression in macrophages may play a role in disease progression, which was then investigated using macrophage-specific deletion of P2Y 6 in a mouse model of atherosclerosis, the Ldlr−/− mouse. This led to the screening and identification of novel antagonist of P2Y 6 with potential therapeutic applications.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The paper primarily explores the role of the P2Y6 receptor in the development of atherosclerosis and attempts to identify new drug candidates that can inhibit this process. Specifically, the researchers found that the P2Y6 receptor plays a crucial role in the formation of foam cells (a type of macrophage that has ingested a large amount of lipids) and that the activation of this receptor promotes the progression of atherosclerosis.

By analyzing atherosclerosis datasets from humans and mice, the research team hypothesized that the expression of P2Y6 in macrophages might be related to the disease process. To verify this hypothesis, they specifically knocked out the P2Y6 receptor in macrophages in an atherosclerosis mouse model (Ldlr−/− mice) and observed that the development of atherosclerotic lesions was significantly inhibited. Further studies revealed how the P2Y6 signaling pathway promotes foam cell formation through mechanisms involving phospholipase Cβ, endoplasmic reticulum calcium release, calreticulin, and scavenger receptor A.

Based on these findings, the research team designed a screening strategy to find compounds that can specifically inhibit P2Y6 signaling. Through virtual screening and functional testing, they identified thiamine pyrophosphate (TPP) as one of the most promising candidate drugs. In a high-cholesterol diet-fed mouse model, TPP significantly reduced the formation of atherosclerotic lesions and decreased lipid accumulation in plaques.

Overall, the problem this paper aims to address is how to develop new therapeutic strategies to prevent or slow the progression of atherosclerosis by targeting the P2Y6 receptor. The research results suggest that inhibitors targeting the P2Y6 receptor could become a new therapy for treating coronary artery disease.